Semaglutide Cuts Fracture Risk 15% in Type 2 Diabetes as Study Shows Greater Weight Loss
Updated
Updated · SciTechDaily · Jun 18
Semaglutide Cuts Fracture Risk 15% in Type 2 Diabetes as Study Shows Greater Weight Loss
3 articles · Updated · SciTechDaily · Jun 18
Summary
A retrospective study presented at ENDO 2026 linked semaglutide to a 15% lower fracture risk in adults with type 2 diabetes versus other weight-loss drugs.
More than 59,000 patients were analyzed from a U.S. electronic health-record database, with 26,324 on semaglutide and 33,555 on dulaglutide, phentermine/topiramate or bupropion/naltrexone.
Semaglutide users also posted larger BMI reductions, while fracture counts were lower at 794 cases versus 1,045 in the comparison group.
The finding stands out because earlier GLP-1 research tied rapid weight loss to bone thinning and higher fracture risk, though researchers said prospective studies are still needed to confirm any bone-health benefit.